Dec 07 2025
Silver (XAG) Forecast: Price Prediction Points Higher if Fed Confirms 2026 Rate Cuts
FDG: One Of The Few Outperformers In 2025
EPU: A Mining ETF With A Large-Cap Bank
Oracle: Why This Selloff Looks Like An Early Christmas Gift
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Lantheus Holdings, Inc. (LNTH)
WPP DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages WPP plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - WPP
3 Incredible Growth Stocks to Buy Now
Down 27%, Should You Buy Adobe Stock Before Dec. 10?
Financial Institutions Is Still Worth Banking On
Netflix Stock Up 13%. Why $82.7 Billion $WBD Buy Makes $NFLX A Sell
Better Buy for 2026: ExxonMobil or Chevron?
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
Value Fund Cuts nCino Stake After $152 Million Quarter: What Long-Term Investors Should Know
Coinbase starts onboarding users again in India, plans for fiat on-ramp next year
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
American Electric Power: Unmatched Reach Make It A Buy
The Merger Fund Q3 2025 Contributors And Detractors
Brookfield, GIC near binding offer for National Storage, Bloomberg News reports
As Growth Accelerates, Is It Time to Buy CrowdStrike Stock?
Cellnex Telecom Is Now A 'Strong Buy'
Exxon Mobil's 43 Year Dividend Streak Looks Secure Despite Falling Earnings
3 Yield-Producing ETFs with Real Staying Power
'PROJECT TALON': Northrop Grumman reveals new 'autonomous wingman'
1 Vanguard ETF I'm Buying in 2026 and Holding Forever
NDMO: I Generally Get Cautious After Sharp Pops Higher (Rating Downgrade)
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Why 10%+ Yields Can Wreck Your Retirement Income
Prediction: Nvidia Stock Is Going to Soar Past $300 in 2026
Kessler Topaz Meltzer & Check, LLP Reminds StubHub Holdings, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
How to trade Apple stock options
Best Marijuana Stocks to Watch Right Now
Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock
Core Scientific's Meltdown Over, Accelerating AI Monetization From FY 2026
Why QuantumScape Stock Got Crushed in November
Better ETF: Is VCLT's Focus on Corporate Bonds the Superior Approach to TLT's U.S. Treasuries?
Paloma Dumps 200,000 Lattice Semiconductor LSCC Shares in $9.8 Million Exit
Why I'm Buying This ETF Like There's No Tomorrow, and Never Selling
Anthony Scaramucci on Solana's Unsung Crypto Story, MSTR "Levered" Play
American Airlines requests notices in Spirit bankruptcy proceedings
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Rio Tinto: Reorganization First, Re-Rating Next
Nayax Considering an Offering of Notes and Warrants in Israel
2 Stocks That Could Soar by 52% and 282%, According to Wall Street
FNDA Is A Good Alternative To Large-Cap ETFs Like VUG
Vaalco Energy: Cash Flow Update
UIVM: Unconvincing Blend Of Value And Momentum
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs
The Cut Countdown
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
DEFT UPCOMING DEADLINE: Faruqi & Faruqi Reminds In DeFi Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 30, 2026 - DEFT
FLY DEADLINE: Faruqi & Faruqi Reminds Firefly Aerospace Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FLY
The Market Is Giving Investors an Unbeatable Opportunity to Buy This Long-Term Artificial Intelligence (AI) Winner (Hint: Not Palantir or Nvidia)
VICI Properties: The Drop I Anticipated Arrived (Rating Upgrade)
STUB DEADLINE: Faruqi & Faruqi Reminds StubHub Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 23, 2026 - STUB
KMX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2026 - KMX
GitLab Shares Plunge. Why It May Be Time to Load Up on the Stock Ahead of the New Year.
FCX DEADLINE: Faruqi & Faruqi Reminds Freeport-McMoran Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FCX
Victoria's Secret: The Brand Is Regaining Momentum
BTDR DEADLINE: Faruqi & Faruqi Reminds Bitdeer Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - BTDR
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel
AVTR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor
Palantir Crushes 63% Growth While UiPath Celebrates Its First Profit
BAX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - BAX
Costco Holds Steady While Walmart Bets Big on E-Commerce Transformation
Top Wall Street analysts favor these 3 stocks for their growth potential
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
OWL DEADLINE: Faruqi & Faruqi Reminds Blue Owl Capital Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - OWL
Victoria's Secret: The Reasons Why The Post-Earnings Rally Is Not Justified
Grocers See Increasing Evidence That Consumers Are Feeling More Strain
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
BST: Technology Options CEF With 7.3% Yield, Growth, No Leverage, But Volatility
US Stormwater Management Market Size Worth USD 15.05 Billion by 2033 | SNS Insider
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Oil-Dri Corporation of America: Upside Hasn't Dried Up Yet
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Silver Price Forecast – ETF Inflows and Supply Deficits Set Stage for $100 Surge in 2026
The Trade Desk Is In War Mode
The Generational Shift I See Now - And My 33 Stocks For What's Coming
ARE INVESTOR LOSSES: Lose Money on Alexandria Real Estate Equities, Inc.? Contact BFA Law before January 26 Securities Class Action Deadline
LRN INVESTOR LOSSES: Lose Money on Stride, Inc.? Contact BFA Law before January 12 Securities Class Action Deadline
MLTX INVESTOR LOSSES: Lose Money on MoonLake Immunotherapeutics? Contact BFA Law before December 15 Securities Class Action Deadline
SNPS INVESTOR LOSSES: Lose Money on Synopsys, Inc.? Contact BFA Law before December 30 Securities Class Action Deadline
JEF INVESTOR LOSSES: Lose Money on Jefferies Financial Group Inc.? Contact BFA Law about its Securities Fraud Investigation
FCX INVESTOR LOSSES: Lose Money on Freeport-McMoRan Inc.? Contact BFA Law before January 12 Securities Class Action Deadline
INSP INVESTOR LOSSES: Lose Money on Inspire Medical Systems, Inc.? Contact BFA Law before January 5 Securities Class Action Deadline
KMX INVESTOR LOSSES: Lose Money on CarMax, Inc.? Contact BFA Law before January 2 Securities Class Action Deadline
JHX INVESTOR LOSSES: Lose Money on James Hardie Industries plc? Contact BFA Law before December 23 Securities Class Action Deadline
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Evaluating Nio Stock's Actual Performance
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Why Carvana (CVNA) stock is rocketing
TSMC: Foundry Monopoly, Inelastic Demand, Robust Pricing Power, And Cheap Valuations
AeroVironment Is On Sale: Modern Defense Runs On Drones, Not Tanks
Credo Technology Stock Is Soaring. Is This a Top AI Play for 2026?
QDVO: A Positive Scenario For 2026
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
Doximity: Elite Margins, AI Growth, And An Attractive Multiple
Risk Disclosure: Trading Contracts for Difference on margin carries a high level of risk, and may not be suitable for all investors. By trading Contracts for Difference, you could sustain a loss of all your deposited funds. BCR makes no recommendations as to the merits of any financial product referred to on our website, emails, or related material(s). The information contained on our website, emails, or related material(s) does not take into consideration prospective clients' trading objectives, financial situations, or investment needs. Before deciding to trade the Contracts for Difference offered by BCR, please ensure that you have read our Product Disclosure Statement ,  Financial Services Guide ,  Target Market Determination and have sought independent professional financial advice to ensure you fully understand the risk involved before trading.
"BCR" is a registered business name of Bacera Co Pty Ltd, Australian Company Number 130 877 137, Australian Financial Services Licence Number 328794.
Business Address: Suite 3, Level 18, 201 Elizabeth Street, SYDNEY NSW 2000 | Registered Address: Level 1, 6-10 O'Connell Street, SYDNEY NSW 2000
The information on this site is not directed at residents of any particular country outside of Australia and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.